Lyka Labs Ltd. (NSE: LYKALABS, BSE: 500259) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹317 Cr, it ranks #2,299 by market cap among the 6,137 Indian listed companies on FinBizNet, and #55 of 86 in Medicinal Chemicals and Botanical Products. At ₹80.99 (as of 25 Oct 2026), the share price is 18.1% below its 52-week high of ₹98.90 and 83.7% above its 52-week low of ₹44.10. The share price is down 15.1% over one year and up 29.5% over three months.
| Current Price | ₹80.99 |
|---|---|
| Market Cap | ₹317 Cr |
| NSE Symbol | LYKALABS |
| BSE Code | 500259 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | -30.6 |
| Return on Equity | -10.74% |
| Return on Assets | -4.25% |
| 52-Week Range | ₹44.10 – ₹98.90 |
| 1-Year Price Change | -15.1% |
| 3-Month Price Change | +29.5% |
| Beta (1Y) | 0.07 |
| Headquarters | Mumbai, Maharashtra |
| Website | www.lykalabs.com |
| Revenue | ₹42 Cr |
|---|---|
| Net Profit | ₹2 Cr |
| Net Margin | 4.8% |
| EPS (Basic) | ₹0.57 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant tablets and combination, proton pump inhibitor, nutraceuticals, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, anti-fungal and bacterial, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. The company offers its products in various forms, including injections, creams, ointments, foams, gels, and lotions. It also exports it
1. Pharmaceuticals-This segment provides pharmaceutical products and pharma related services.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Lyka Labs Ltd. | ₹317 Cr | -30.6 | -10.74% | ₹42 Cr | -15.1% |
Listed by market capitalisation. Ratios are shown for context only.
Lyka Labs Ltd. is trading at ₹80.99, with a market capitalisation of ₹317 Cr.
Lyka Labs Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Lyka Labs Ltd. has a P/E of -30.6 and a return on equity of -10.74%.
Lyka Labs Ltd. is listed on the NSE under the symbol LYKALABS and on the BSE under the scrip code 500259.
Lyka Labs Ltd.'s share price is down 15.1% over one year and up 29.5% over three months. Its 52-week range is ₹44.10 to ₹98.90.
In Q1 FY27, Lyka Labs Ltd. reported revenue of ₹42 Cr and net profit of ₹2 Cr, with basic EPS of ₹0.57 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.